3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Colorectal Neoplasms
22
Neoplasms
13
Colonic Neoplasms
10
Breast Neoplasms
10
Venous Thromboembolism
8
Prostatic Neoplasms
8
Multiple Myeloma
7
Recurrence
6
Polycythemia Vera
6
Carcinoma, Non-Small-Cell Lung
6
Thrombocythemia, Essential
4
Neoplasms, Plasma Cell
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Thrombosis
2
Sarcoma
2
Rectal Neoplasms
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms by Site
2
Myocardial Infarction
2
Lung Neoplasms
2
Intestinal Neoplasms
2
Intestinal Diseases
2
Inflammation
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Interventions
Etoposide
10
Cisplatin
9
Cyclophosphamide
7
etoposide phosphate
5
Paclitaxel
5
Ifosfamide
5
Granulocyte Colony-Stimulating Factor
5
Carboplatin
5
fludarabine
4
Sirolimus
4
Gemcitabine
4
pembrolizumab
3
fludarabine phosphate
3
Sunitinib
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bleomycin
3
Bevacizumab
3
Automobiles
3
tremelimumab
2
sodium thiosulfate
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
durvalumab
2
Vorinostat
2
Stem Cell Transplantation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Germ Cell and Embryonal
×
Aspirin
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled